FDA Approved Expanded Indication For Novartis Leqvio To Include Treatment Of Adults With High Ldl-c And Who Are At Increased Risk Of Heart Disease
Portfolio Pulse from Charles Gross
The US Food and Drug Administration (FDA) has approved a label update for Novartis' Leqvio (inclisiran) to enable its use in patients with elevated LDL-C who have an increased risk of heart disease. This includes patients with comorbidities such as hypertension and diabetes who have not yet had a first cardiovascular event.
July 10, 2023 | 11:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis' Leqvio has received FDA approval for a label update, expanding its use to patients with high LDL-C at risk of heart disease. This could potentially increase the drug's market and revenue for Novartis.
The FDA approval for the label update of Leqvio allows Novartis to market the drug to a wider patient population. This could potentially increase the sales of the drug, positively impacting Novartis' revenue in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100